Introduction

Alzheimer’s disease (AD) is a progressive brain disorder, and one of the most common causes of dementia and amnesia. Due to the complex pathogenesis of AD, the underlying mechanisms remain unclear. Although scientists have made increasing efforts to develop drugs for AD, no effective therapeutic agents have been found.

Objectives

Natural products and their constituents have shown promise for treating neurodegenerative diseases, including AD. Thus, in-depth study of medical plants, and the main active ingredients thereof against AD, is necessary to devise therapeutic agents.

Methods

In this study, N2a/APP cells and SAMP8 mice were employed as in vitro and in vivo models of AD. Multiple molecular biological methods were used to investigate the potential therapeutic actions of oxyphylla A, and the underlying mechanisms.

Results

Results showed that oxyphylla A, a novel compound extracted from Alpinia oxyphylla, could reduce the expression levels of amyloid precursor protein (APP) and amyloid beta (Aβ) proteins, and attenuate cognitive decline in SAMP8 mice. Further investigation of the underlying mechanisms showed that oxyphylla A exerted an antioxidative effect through the Akt-GSK3β and Nrf2-Keap1-HO-1 pathways.

Conclusions.

Taken together, our results suggest a new horizon for the discovery of therapeutic agents for AD.

中文翻译：

---

Oxyphylla A 在阿尔茨海默病的体外和体内小鼠模型中通过 Akt-GSK3β 和 Nrf2-Keap1-HO-1 通路改善认知缺陷并减轻神经病理学

介绍

阿尔茨海默病 (AD) 是一种进行性脑部疾病，也是导致痴呆和健忘症的最常见原因之一。由于AD的发病机制复杂，其潜在机制仍不清楚。尽管科学家们已经做出了越来越多的努力来开发治疗 AD 的药物，但尚未发现有效的治疗药物。

目标

天然产物及其成分已显示出治疗包括 AD 在内的神经退行性疾病的前景。因此，有必要对药用植物及其抗 AD 的主要活性成分进行深入研究，以设计治疗剂。

方法

在这项研究中，N2a/APP 细胞和 SAMP8 小鼠被用作AD的体外和体内模型。采用多种分子生物学方法研究了木柴 A 的潜在治疗作用及其潜在机制。

结果

结果表明，从木炭中提取的一种新型化合物 oxyphylla A 可以降低 SAMP8 小鼠的淀粉样前体蛋白 (APP) 和淀粉样β (Aβ) 蛋白的表达水平，并减轻认知能力下降。对潜在机制的进一步研究表明，木柴 A 通过 Akt-GSK3β 和 Nrf2-Keap1-HO-1 途径发挥抗氧化作用。

结论。

总之，我们的结果为发现 AD 治疗药物开辟了新的视野。